Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATADOR breast cancer adjuvant chemotherapy trial
NL-OMON23149Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2004
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, cyclophosphamide, docetaxel, pegfilgrastim and trastuzumab in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Started Oct 2004; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON23149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23149.